<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/"><channel><title>心血管出版物</title><link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;v=2.17.9.post6+86293ac&amp;utm_source=Chrome&amp;utm_content=1vUePJ4Z_tESA AXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20230913081451&amp;fc=20230708114047&amp;utm_campaign=出版-2<description>心血管亮点：PubMed 的最新结果</description><atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;v=2.17.9.post6+86293ac&amp;utm_source=Chrome&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20230913081451&amp;fc=20230708114047&amp;utm_campaign=pubmed-2" rel="self"></atom:link><docs> http://www.rssboard.org/rss-specification</docs><generator> PubMed RSS 源 (2.17.9.post6+86293ac)</generator><language> zh</language><lastbuilddate> 2023 年 9 月 13 日星期三 12:14:54 +0000</lastbuilddate><pubDate> Wed, 13 Sep 2023 06:00:00 -0400</pubDate><ttl> 120</ttl><item><title>心脏磁共振生物标志物作为心肌疾病心血管试验的替代终点</title><link/>https://pubmed.ncbi.nlm.nih.gov/37700499/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230913081451&amp;v=2.17.9.post6+86293ac<description>心脏磁共振在心肌疾病患者的诊断、风险分层和管理方面提供了多个方面。特别是，其精确监测疾病活动的功能有助于量化对新疗法的反应。这篇综述批判性地评价了心脏磁共振成像的价值生物标志物作为前瞻性临床试验的替代终点。主要重点是全面概述已建立的心脏磁的价值... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Sep 13:ehad510.doi: 10.1093/eurheartj/ehad510. 印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">心脏磁共振在心肌疾病患者的诊断、风险分层和管理方面提供了多个方面。特别是，其精确监测疾病活动的功能有助于量化对新疗法的反应。这篇综述批判性地评价了心脏磁共振成像的价值生物标志物作为前瞻性临床试验的替代终点。主要重点是全面概述已确定的心脏磁共振参数在心肌疾病中的价值。这些疾病包括心力衰竭、心脏淀粉样变性、铁过载心肌病、肥厚性心肌病、心脏肿瘤和炎症性心肌病如心肌炎和结节病。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37700499/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230913081451&v=2.17.9.post6+86293ac">37700499</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad510>10.1093/eurheartj/ehad510</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37700499</guid><pubDate> Wed, 13 Sep 2023 06:00:00 -0400</pubDate><dc:creator>多米尼克·本茨</dc:creator><dc:creator>克里斯托夫·格拉尼</dc:creator><dc:creator>帕纳吉奥蒂斯·安提奥克斯</dc:creator><dc:creator>博巴克·海达里</dc:creator><dc:creator>马克·科林·吉斯勒</dc:creator><dc:creator>银阁</dc:creator><dc:creator>萨拉·AM·卡迪</dc:creator><dc:creator>莎米拉·多巴拉</dc:creator><dc:creator>邝伟文</dc:creator><dc:date>2023-09-13</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>心脏磁共振生物标志物作为心肌疾病心血管试验的替代终点</dc:title><dc:identifier>下午:37700499</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad510</dc:identifier></item><item><title>对具有免疫特征的基质细胞控制的早期妊娠的时空洞察</title><link/>https://pubmed.ncbi.nlm.nih.gov/37699390/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230913081451&amp;v=2.17.9.post6+86293ac<description>连接胚胎着床和胎盘的子宫内膜蜕膜化是短暂的，但对于成功妊娠至关重要，然而，这一点尚未得到系统研究。在这里，我们使用 scStereo-seq 技术来空间可视化和定义由不同的免疫、内皮、早期妊娠小鼠的滋养层细胞和蜕膜基质细胞 (DSC)。我们解开了 DSC 转分化轨迹，并令人惊讶地发现了一种双重功能…… </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 年 9 月 7 日：S0092-8674(23)00909-1. doi: 10.1016/j.cell.2023.08.020. 印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">连接胚胎着床和胎盘的子宫内膜蜕膜化是短暂的，但对于成功妊娠至关重要，然而，这一点尚未得到系统研究。在这里，我们使用 scStereo-seq 技术来空间可视化和定义由不同的免疫、内皮、早期妊娠小鼠的滋养层细胞和蜕膜基质细胞 (DSC)。我们解开了 DSC 转分化轨迹，并令人惊讶地发现了一种具有双重功能的免疫特征 DSC (iDSC)。我们发现，未成熟的 DSC 会吸引免疫细胞并诱导蜕膜血管生成蜕膜化起始期间的间充质-上皮过渡枢纽。iDSC 能够招募和抑制免疫细胞、控制血管形成并分别促进免疫细胞组装和血管枢纽处的细胞溶解，以在后期建立蜕膜稳态。导致免疫细胞异常积累血管中枢，它破坏了蜕膜中枢的规范，并最终导致 DBA/2 交配的 CBA/J 小鼠妊娠并发症。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37699390/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230913081451&v=2.17.9.post6+86293ac">37699390</a> | DOI： <a href=https://doi.org/10.1016/j.cell.2023.08.020>10.1016/j.cell.2023.08.020</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37699390</guid><pubDate> Tue, 12 Sep 2023 06:00:00 -0400</pubDate><dc:creator>杨敏</dc:creator><dc:creator>王珍妮</dc:creator><dc:creator>孟凡举</dc:creator><dc:creator>张飞翔</dc:creator><dc:creator>沉慧</dc:creator><dc:creator>克斯汀·基特</dc:creator><dc:creator>刘腾飞</dc:creator><dc:creator>韦涛</dc:creator><dc:creator>杜鹏</dc:creator><dc:date>2023-09-12</dc:date><dc:source>细胞</dc:source><dc:title>对具有免疫特征的基质细胞控制的早期妊娠的时空洞察</dc:title><dc:identifier>下午:37699390</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.08.020</dc:identifier></item><item><title> SPHK2/S1P 轴改变平滑肌细胞组蛋白乙酰基可促进肺动脉高压</title><link/>https://pubmed.ncbi.nlm.nih.gov/37698017/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230913081451&amp;v=2.17.9.post6+86293ac<description>结论：人肺动脉平滑肌细胞中 SPHK2 的表达及其对可逆组蛋白 H3K9 乙酰化的激活代表了可以减轻 PH 血管重塑的新治疗靶点。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Circ Res. 2023 年 9 月 12 日。doi：10.1161/CIRCRESAHA.123.322740。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：对肺动脉高压 (PH) 血管重塑的表观遗传调控知之甚少。转录调节、组蛋白乙酰化密码改变染色质可及性以促进转录激活。我们的目标是确定破坏 PH 中表观遗传平衡的上游机制。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：人肺动脉平滑肌细胞 (PASMC)、人特发性肺动脉高压 (iPAH)：人 PASMC、iPAH 肺组织、衰竭供体肺组织、人肺微血管内皮细胞、iPAH:PASMC 和非 iPAH:PASMC RNA-利用 seq 数据库、NanoString nCounter 以及使用核酸酶进行靶标切割和释放来研究组蛋白乙酰化、超乙酰化靶标、蛋白质和基因表达、鞘脂激活、细胞增殖和基因靶标识别。SPHK2（鞘氨醇激酶 2）敲除与缺氧 3 周后对照 C57BL/6NJ 小鼠并评估 PH 指数。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：我们发现人类 PASMC 易受转录促进表观遗传介质组蛋白乙酰化的影响，导致转录机制发生改变，并证实其在 PH:PASMC 细胞中的病理存在。我们报告 SPHK2 在 iPAH 肺中升高高达 20 倍在 PH 发病过程中，核 SPHK2 激活核生物活性脂质 S1P（1-磷酸鞘氨醇）催化酶，并通过 EMAP 介导转录调节组蛋白 H3K9 乙酰化（乙酰组蛋白 H3 赖氨酸 9 [Ac-H3K9]） （内皮单核细胞激活多肽） II. 在 iPAH 肺中，我们发现可逆表观遗传转录调节剂 Ac-H3K9:H3 的比例升高了 4 倍。SPHK2 的缺失抑制了小鼠缺氧诱导的 PH 和 Ac-H3K9。我们发现肺血管内皮细胞是 EMAP II/SPHK2/S1P 轴的启动因子，通过组蛋白 H3K9 的高度乙酰化，改变具有 PASMC 特异性的乙酰组。利用靶标下的切割并使用核酸酶释放，我们进一步表明 EMAP II 介导的SPHK2 有潜力通过超乙酰化 KLF4 顺式调节元件来修饰多能性因子 KLF4（Krüppel 样因子 4）的局部转录机制，而 SPHK2 的删除和靶向抑制则可以挽救改变转录的 Ac-H3K9。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：人肺动脉平滑肌细胞中 SPHK2 的表达及其对可逆组蛋白 H3K9 乙酰化的激活代表了可以减轻 PH 血管重塑的新治疗靶点。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37698017/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230913081451&v=2.17.9.post6+86293ac">37698017</a> | DOI： <a href=https://doi.org/10.1161/CIRCRESAHA.123.322740>10.1161/CIRCRESAHA.123.322740</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37698017</guid><pubDate> Tue, 12 Sep 2023 06:00:00 -0400</pubDate><dc:creator> A 杜沙尼 CU 拉纳辛哈</dc:creator><dc:creator>玛吉·霍洛汉</dc:creator><dc:creator>卡林·博格</dc:creator><dc:creator>黛博拉·多纳休</dc:creator><dc:creator>拉斐尔·D·库克</dc:creator><dc:creator>马丁·格里格</dc:creator><dc:creator>安德鲁·金</dc:creator><dc:creator>维多利亚·普罗普利斯</dc:creator><dc:creator>弗朗西斯·卡斯特利诺</dc:creator><dc:creator>玛格丽特·施瓦茨</dc:creator><dc:date>2023-09-12</dc:date><dc:source>流通研究</dc:source><dc:title>SPHK2/S1P 轴改变平滑肌细胞组蛋白乙酰基可促进肺动脉高压</dc:title><dc:identifier>下午：37698017</dc:identifier><dc:identifier> doi:10.1161/CIRCRESAHA.123.322740</dc:identifier></item><item><title>实施预防科学以消除医疗保健不平等，实现心血管健康：美国心脏协会的科学声明</title><link/>https://pubmed.ncbi.nlm.nih.gov/37698007/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230913081451&amp;v=2.17.9.post6+86293ac<description>预防心血管及相关疾病是实现理想心血管健康以改善个人和社区整体健康和福祉的基础。健康的社会决定因素和医疗保健不平等会对理想的心血管健康和疾病预防产生不利影响。有效和公平的方式需要协调的多学科和多层次的方法。在这份科学声明中，我们研究...... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 9 月 12 日。doi：10.1161/CIR.0000000000001171。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">预防心血管及相关疾病是实现理想心血管健康以改善个人和社区整体健康和福祉的基础。健康的社会决定因素和医疗保健不平等会对理想的心血管健康和疾病预防产生不利影响。有效和公平的方式需要协调的多学科和多层次方法。在这份科学声明中，我们在利用现有资源减少医疗保健不平等并优化预防性心血管护理服务的背景下，研究了实现理想心血管健康及其相关状况的障碍我们主要讨论（1）涉及直接患者护理的跨医疗保健环境的干预措施，（2）利用医疗保健技术，（3）优化多专业/多专业合作和干预措施，（4）吸引当地社区，以及（5）改善社区。通过与健康相关的政府政策来改善环境，所有这些政策的重点都是使所有人都享有公平的理想心血管健康。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37698007/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230913081451&v=2.17.9.post6+86293ac">37698007</a> | DOI： <a href=https://doi.org/10.1161/CIR.0000000000001171>10.1161/CIR.0000000000001171</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37698007</guid><pubDate> Tue, 12 Sep 2023 06:00:00 -0400</pubDate><dc:creator>阿南迪塔·阿加瓦拉</dc:creator><dc:creator>贾迪普·帕特尔</dc:creator><dc:creator>詹娜·斯蒂芬斯</dc:creator><dc:creator>沙马里尔·罗伯森</dc:creator><dc:creator>朱厄尔·斯科特</dc:creator><dc:creator>特里萨·贝基</dc:creator><dc:creator>伊丽莎白·杰克逊</dc:creator><dc:creator>美国心脏协会预防科学委员会、流行病学和预防委员会、心血管和中风护理委员会、临床心脏病学委员会、生活方式和心脏代谢健康委员会、周围血管疾病委员会、护理质量和结果研究委员会以及中风理事会</dc:creator><dc:date>2023-09-12</dc:date><dc:source>循环</dc:source><dc:title>实施预防科学以消除医疗保健不平等，实现心血管健康：美国心脏协会的科学声明</dc:title><dc:identifier>下午：37698007</dc:identifier><dc:identifier>号码：10.1161/CIR.0000000000001171</dc:identifier></item><item><title>导管消融可改善 AF 和终末期 HF 患者的预后</title><link/>https://pubmed.ncbi.nlm.nih.gov/37697073/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230913081451&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Nat Rev Cardiol。2023 年 9 月 11 日。doi：10.1038/s41569-023-00932-9。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37697073/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230913081451&v=2.17.9.post6+86293ac">37697073</a> | DOI： <a href=https://doi.org/10.1038/s41569-023-00932-9>10.1038/s41569-023-00932-9</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37697073</guid><pubDate> Mon, 11 Sep 2023 06:00:00 -0400</pubDate><dc:creator>卡琳娜·黄</dc:creator><dc:date>2023-09-11</dc:date><dc:source> 《自然》评论、心脏病学</dc:source><dc:title>导管消融可改善 AF 和终末期 HF 患者的预后</dc:title><dc:identifier>下午:37697073</dc:identifier><dc:identifier> doi:10.1038/s41569-023-00932-9</dc:identifier></item><item><title>梗死重塑中的心脏周细胞多样性：不仅仅是血管支持细胞？</title><link/> https://pubmed.ncbi.nlm.nih.gov/37695834/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230913081451&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>. 2023 年 9 月 12 日；148(11):899-902. doi: 10.1161/CIRCULATIONAHA.123.065676. Epub 2023 年 9 月 11 日。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37695834/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230913081451&v=2.17.9.post6+86293ac">37695834</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065676>10.1161/CIRCULATIONAHA.123.065676</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37695834</guid><pubDate> Mon, 11 Sep 2023 06:00:00 -0400</pubDate><dc:creator>托马斯·摩尔-莫里斯</dc:creator><dc:creator>西尔维娅·M·埃文斯</dc:creator><dc:date>2023-09-11</dc:date><dc:source>循环</dc:source><dc:title>梗死重塑中的心脏周细胞多样性：不仅仅是血管支持细胞？</dc:title><dc:identifier>下午:37695834</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.065676</dc:identifier></item><item><title> Cosentino 和 Marino 关于文章“在 COVID-19 mRNA 疫苗后心肌炎中检测到的循环刺突蛋白”的信函</title><link/>https://pubmed.ncbi.nlm.nih.gov/37695833/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230913081451&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>. 2023 年 9 月 12 日；148(11):906-907. doi: 10.1161/CIRCULATIONAHA.123.064000. Epub 2023 年 9 月 11 日。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37695833/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230913081451&v=2.17.9.post6+86293ac">37695833</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.064000>10.1161 / CIRCULATIONAHA.123.064000</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37695833</guid><pubDate> Mon, 11 Sep 2023 06:00:00 -0400</pubDate><dc:creator>马可·科森蒂诺</dc:creator><dc:creator>弗兰卡·马里诺</dc:creator><dc:date>2023-09-11</dc:date><dc:source>循环</dc:source><dc:title>Cosentino 和 Marino 关于文章“在 COVID-19 mRNA 疫苗后心肌炎中检测到的循环刺突蛋白”的信函</dc:title><dc:identifier>下午:37695833</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.064000</dc:identifier></item><item><title>血管内成像引导下经皮冠状动脉介入治疗对慢性完全闭塞的预后影响</title><link/>https://pubmed.ncbi.nlm.nih.gov/37695832/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230913081451&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>. 2023 年 9 月 12 日；148(11):903-905. doi: 10.1161/CIRCULATIONAHA.123.065876. Epub 2023 年 9 月 11 日。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37695832/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230913081451&v=2.17.9.post6+86293ac">37695832</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065876>10.1161 / CIRCULATIONAHA.123.065876</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37695832</guid><pubDate> Mon, 11 Sep 2023 06:00:00 -0400</pubDate><dc:creator>洪大卫</dc:creator><dc:creator>金尚民</dc:creator><dc:creator>李相耀</dc:creator><dc:creator>崔基弘</dc:creator><dc:creator>宋永斌</dc:creator><dc:creator>李正英</dc:creator><dc:creator>李承宰</dc:creator><dc:creator>尹京浩</dc:creator><dc:creator>赵在英</dc:creator><dc:creator>金灿俊</dc:creator><dc:creator>安孝石</dc:creator><dc:creator>南昌旭</dc:creator><dc:creator>尹赫俊</dc:creator><dc:creator>朴容焕</dc:creator><dc:creator>王秀利</dc:creator><dc:creator>郑振玉</dc:creator><dc:creator>宋必尚</dc:creator><dc:creator>都俊亨</dc:creator><dc:creator>赵尚浩</dc:creator><dc:creator>尹昌焕</dc:creator><dc:creator>姜敏奎</dc:creator><dc:creator>许真仙</dc:creator><dc:creator>李宽勇</dc:creator><dc:creator>林英孝</dc:creator><dc:creator>赵润亨</dc:creator><dc:creator>赵镇万</dc:creator><dc:creator>张宇振</dc:creator><dc:creator>千国镇</dc:creator><dc:creator>朴泽奎</dc:creator><dc:creator>杨正勋</dc:creator><dc:creator>崔胜赫</dc:creator><dc:creator>权贤哲</dc:creator><dc:creator>韩柱容</dc:creator><dc:creator>李柱明</dc:creator><dc:creator>翻新综合体 PCI 调查员</dc:creator><dc:date>2023-09-11</dc:date><dc:source>循环</dc:source><dc:title>血管内成像引导下经皮冠状动脉介入治疗对慢性完全闭塞的预后影响</dc:title><dc:identifier>下午:37695832</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.065876</dc:identifier></item><item><title>为什么预防心脏病学的新疗法可能面临马拉松而不是短跑</title><link/>https://pubmed.ncbi.nlm.nih.gov/37695831/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230913081451&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>. 2023 年 9 月 12 日；148(11):859-861. doi: 10.1161/CIRCULATIONAHA.122.063099. Epub 2023 年 9 月 11 日。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37695831/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230913081451&v=2.17.9.post6+86293ac">37695831</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.122.063099>10.1161/CIRCULATIONAHA.122.063099</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37695831</guid><pubDate> Mon, 11 Sep 2023 06:00:00 -0400</pubDate><dc:creator>乔安娜·卡瓦利尔</dc:creator><dc:creator>尼尚·P·沙阿</dc:creator><dc:creator>迈克尔·A·炽热</dc:creator><dc:date>2023-09-11</dc:date><dc:source>循环</dc:source><dc:title>为什么预防心脏病学的新疗法可能面临马拉松而不是短跑</dc:title><dc:identifier>下午:37695831</dc:identifier><dc:identifier> doi:10.1161/循环AHA.122.063099</dc:identifier></item><item><title> Schwartz 和 Prasad 关于文章“在 COVID-19 mRNA 疫苗后心肌炎中检测到的循环尖峰蛋白”的信函</title><link/>https://pubmed.ncbi.nlm.nih.gov/37695830/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230913081451&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>. 2023 年 9 月 12 日；148(11):908-909. doi: 10.1161/CIRCULATIONAHA.123.064414. Epub 2023 年 9 月 11 日。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37695830/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230913081451&v=2.17.9.post6+86293ac">37695830</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.064414>10.1161/CIRCULATIONAHA.123.064414</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37695830</guid><pubDate> Mon, 11 Sep 2023 06:00:00 -0400</pubDate><dc:creator>迈克尔·大卫·施瓦茨</dc:creator><dc:creator>卡姆拉·K·普拉萨德</dc:creator><dc:date>2023-09-11</dc:date><dc:source>循环</dc:source><dc:title>Schwartz 和 Prasad 关于文章“在 COVID-19 mRNA 疫苗后心肌炎中检测到的循环尖峰蛋白”的信函</dc:title><dc:identifier>下午:37695830</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.064414</dc:identifier></item><item><title> Yonker 等人对有关文章“在 COVID-19 mRNA 疫苗后心肌炎中检测到的循环尖峰蛋白”的信件的回复</title><link/>https://pubmed.ncbi.nlm.nih.gov/37695829/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230913081451&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>. 2023 年 9 月 12 日；148(11):910-911. doi: 10.1161/CIRCULATIONAHA.123.065629. Epub 2023 年 9 月 11 日。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37695829/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230913081451&v=2.17.9.post6+86293ac">37695829</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065629>10.1161/CIRCULATIONAHA.123.065629</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37695829</guid><pubDate> Mon, 11 Sep 2023 06:00:00 -0400</pubDate><dc:creator>莱尔·M·扬克</dc:creator><dc:creator>阿莱西奥·法萨诺</dc:creator><dc:creator>大卫·R·沃尔特</dc:creator><dc:date>2023-09-11</dc:date><dc:source>循环</dc:source><dc:title>Yonker 等人对有关文章“在 COVID-19 mRNA 疫苗后心肌炎中检测到的循环尖峰蛋白”的信件的回复</dc:title><dc:identifier>下午:37695829</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.065629</dc:identifier></item><item><title>通过血脑屏障的荷尔蒙把关控制着蚂蚁的种姓特定行为</title><link/>https://pubmed.ncbi.nlm.nih.gov/37683635/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230913081451&amp;v=2.17.9.post6+86293ac<description>在这里，我们揭示了血脑屏障 (BBB) 在调节蚂蚁复杂的社会行为中发挥的意想不到的作用。利用 scRNA-seq，我们发现了一种称为保幼激素酯酶 (Jhe) 的关键激素降解酶位于 BBB 中。 ），我们表明这种定位控制着进入大脑的保幼激素（JH3）的水平。Jhe水平的操纵会重新编程蚂蚁种姓之间的大脑转录组。虽然蚂蚁Jhe被保留并在BBB内的细胞内发挥作用，... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 年 8 月 24 日：S0092-8674(23)00856-5. doi: 10.1016/j.cell.2023.08.002. 印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">在这里，我们揭示了血脑屏障 (BBB) 在调节蚂蚁复杂的社会行为中发挥的意想不到的作用。利用 scRNA-seq，我们发现了一种称为保幼激素酯酶 (Jhe) 的关键激素降解酶位于 BBB 中。 ），我们表明这种定位控制着进入大脑的保幼激素（JH3）的水平。Jhe 水平的操纵会重新编程蚂蚁种姓之间的大脑转录组。尽管蚂蚁 Jhe 被保留并在 BBB 内发挥细胞内功能，但我们发现果蝇Jhe 天然存在于细胞外。蚂蚁 Jhe 在果蝇 BBB 中的异源表达改变了苍蝇的行为，以模仿蚂蚁中所看到的行为。最引人注目的是，操纵蚂蚁中的 Jhe 水平重新编程了工蚁种姓之间的复杂行为。因此，我们的研究揭示了一种非凡的、潜在的BBB 作为调节社会行为的神经激素途径的分子守门人的保守作用。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37683635/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230913081451&v=2.17.9.post6+86293ac">37683635</a> | DOI： <a href=https://doi.org/10.1016/j.cell.2023.08.002>10.1016/j.cell.2023.08.002</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37683635</guid><pubDate> Fri, 08 Sep 2023 06:00:00 -0400</pubDate><dc:creator>鞠林洋</dc:creator><dc:creator>卡尔·M·格拉斯塔德</dc:creator><dc:creator>盛立红</dc:creator><dc:creator>扬科·戈斯波西奇</dc:creator><dc:creator>卡勒姆·J·金威尔</dc:creator><dc:creator>肖恩·M·戴维森</dc:creator><dc:creator>莎拉·D·科赫</dc:creator><dc:creator>罗伯托·博纳西奥</dc:creator><dc:creator>雪莱·伯杰</dc:creator><dc:date>2023-09-08</dc:date><dc:source>细胞</dc:source><dc:title>通过血脑屏障的荷尔蒙把关控制着蚂蚁的种姓特定行为</dc:title><dc:identifier>下午:37683635</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.08.002</dc:identifier></item><item><title> Patescibacteria 的基因操作为微生物暗物质和表生生活方式提供了机制见解</title><link/>https://pubmed.ncbi.nlm.nih.gov/37683634/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230913081451&amp;v=2.17.9.post6+86293ac<description> Patescibacteria，也称为候选辐射门 (CPR)，是一组多样化的细菌，构成了微生物暗物质中不成比例的大部分。它的少数培养成员主要属于糖杆菌，在宿主放线菌上作为表生菌生长。由于缺乏合适的工具，这种生活方式的遗传基础和 Patescibacteira 的其他独特特征仍未得到探索。在这里，我们表明糖细菌表现出天然的能力，并且我们利用... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 年 8 月 30 日：S0092-8674(23)00906-6. doi: 10.1016/j.cell.2023.08.017. 印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> Patescibacteria，也称为候选辐射门 (CPR)，是一组多样化的细菌，构成了微生物暗物质中不成比例的大部分。它的少数培养成员主要属于糖杆菌，在宿主放线菌上作为表生菌生长。由于缺乏合适的工具，这种生活方式的遗传基础和 Patescibacteira 的其他独特特征仍未被探索。在这里，我们表明糖杆菌表现出天然的能力，并且我们利用这种特性进行基因操作。荧光蛋白标记的糖杆菌的成像提供了高时空解决伴随表生生长的现象，转座子插入测序（Tn-seq）全基因组筛选揭示了神秘的糖细菌基因对其宿主生长的贡献。最后，我们利用宏基因组数据提供基于蛋白质结构的尖端技术支持 Southlakia epibion​​ticum 菌株及其相应宿主以色列放线菌作为解锁表生生活方式分子基础的模型系统的生物信息资源。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37683634/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230913081451&v=2.17.9.post6+86293ac">37683634</a> | DOI： <a href=https://doi.org/10.1016/j.cell.2023.08.017>10.1016/j.cell.2023.08.017</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37683634</guid><pubDate> Fri, 08 Sep 2023 06:00:00 -0400</pubDate><dc:creator>王亚熙</dc:creator><dc:creator>拉里·加拉格尔</dc:creator><dc:creator>皮娅·安德拉德</dc:creator><dc:creator>刘安迪</dc:creator><dc:creator>伊恩·R·汉弗莱斯</dc:creator><dc:creator>塞尔达·图卡斯兰</dc:creator><dc:creator>凯文·J·卡特勒</dc:creator><dc:creator>马里奥·L·阿列塔-奥尔蒂斯</dc:creator><dc:creator>李亚桥</dc:creator><dc:creator>马修·雷迪</dc:creator><dc:creator>杰弗里·麦克莱恩</dc:creator><dc:creator>钱聪</dc:creator><dc:creator>大卫·贝克</dc:creator><dc:creator>尼廷·S·巴利加</dc:creator><dc:creator>布鲁克彼得森</dc:creator><dc:creator>约瑟夫·D·穆古斯</dc:creator><dc:date>2023-09-08</dc:date><dc:source>细胞</dc:source><dc:title>Patescibacteria 的基因操作为微生物暗物质和表生生活方式提供了机制见解</dc:title><dc:identifier>下午:37683634</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.08.017</dc:identifier></item><item><title>环氧二十碳三烯酸通过 IFN-I 信号传导预防病毒性心肌炎的心脏功能障碍</title><link/>https://pubmed.ncbi.nlm.nih.gov/37681352/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230913081451&amp;v=2.17.9.post6+86293ac<description>心肌炎是一种具有挑战性的心脏炎症性疾病，需要更好地了解其发病机制以开发特异性药物疗法。环氧二十碳三烯酸（EET）是由花生四烯酸的 CYP（细胞色素 P450）酶合成的活性分子，并水解为活性较低的二羟基二十碳三烯酸由 sEH（可溶性环氧化物水解酶）产生的 EET 被认为具有抗炎活性。在这里，我们研究了 EET 是否具有免疫调节活性并发挥... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Circ Res. 2023 年 9 月 8 日。doi：10.1161/CIRCRESAHA.123.322619。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">心肌炎是一种具有挑战性的心脏炎症性疾病，需要更好地了解其发病机制以开发特异性药物疗法。环氧二十碳三烯酸（EET）是由花生四烯酸的 CYP（细胞色素 P450）酶合成的活性分子，并水解为活性较低的二羟基二十碳三烯酸sEH（可溶性环氧化物水解酶）产生的 EET 被认为具有抗炎活性。在此，我们研究了 EET 是否具有免疫调节活性，并对柯萨奇 B3 病毒引起的心肌炎发挥保护作用。病毒感染心肌炎患者和心肌炎患者中的类二十烷酸环氧化物和二醇水平在小鼠心脏中，与柯萨奇 B3 病毒感染后 sEH 的表达和活性增加相关。使用 sEH 抑制剂可预防柯萨奇 B3 病毒引起的心脏功能障碍和炎症浸润。重要的是，EET/sEH 抑制剂治疗可减弱病毒感染或改善病毒感染通过激活 I 型 IFN（干扰素）信号传导来抵抗耐药性。在分子水平上，EET 增强了 GSK3β（糖原合酶激酶 3 beta）和 TBK1（TANK 结合激酶 1）之间的相互作用，以促进 IFN-β 的产生。我们的研究结果表明， EET 和 sEH 抑制剂可预防柯萨奇 B3 病毒引起的心肌炎的进展，特别是通过增加 IFN 的产生来促进病毒抵抗力。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37681352/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230913081451&v=2.17.9.post6+86293ac">37681352</a> | DOI： <a href=https://doi.org/10.1161/CIRCRESAHA.123.322619>10.1161/CIRCRESAHA.123.322619</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37681352</guid><pubDate> Fri, 08 Sep 2023 06:00:00 -0400</pubDate><dc:creator>周周</dc:creator><dc:creator>张敏</dc:creator><dc:creator>赵成成</dc:creator><dc:creator>徐高</dc:creator><dc:creator>郑文</dc:creator><dc:creator>吴俊芳</dc:creator><dc:creator>陈陈</dc:creator><dc:creator>英格丽·弗莱明</dc:creator><dc:creator>胡炯</dc:creator><dc:creator>王道文</dc:creator><dc:date>2023-09-08</dc:date><dc:source>流通研究</dc:source><dc:title>环氧二十碳三烯酸通过 IFN-I 信号传导预防病毒性心肌炎的心脏功能障碍</dc:title><dc:identifier>下午：37681352</dc:identifier><dc:identifier> doi:10.1161/CIRCRESAHA.123.322619</dc:identifier></item><item><title>阿哌沙班剂量与心房颤动和严重慢性肾脏病患者安全性和有效性结果的关系</title><link/>https://pubmed.ncbi.nlm.nih.gov/37681341/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230913081451&amp;v=2.17.9.post6+86293ac<description>结论：与 2.5 mg 相比，使用 5 mg 阿哌沙班与心房颤动和严重慢性肾脏病患者的出血风险较高相关，但中风/全身性栓塞或死亡风险没有差异，支持阿哌沙班的剂量建议欧洲药品管理局以肾功能为基础，与美国食品和药物管理局发布的不同。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 9 月 8 日。doi：10.1161/CIRCULATIONAHA.123.065614。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：美国食品和药物管理局和欧洲药品管理局根据肾功能对房颤患者阿哌沙班剂量的建议不一致。慢性肾病患者的最佳阿哌沙班剂量仍不清楚。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：通过使用来自 Optum Labs 数据仓库的去识别化电子健康记录数据，确定了 2013 年至 2021 年间开始服用阿哌沙班的心房颤动和慢性肾脏病 4/5 期患者。阿哌沙班剂量（5 与 2.5 mg），通过治疗权重的逆概率调整基线特征。使用细灰色次分布风险模型来解释死亡的竞争风险。使用 Cox 回归来检查阿哌沙班的死亡风险剂量。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：在 4313 名阿哌沙班新使用者中，1705 名（40%）接受 5 mg 治疗，2608 名（60%）接受 2.5 mg。接受 5 mg 阿哌沙班治疗的患者更年轻（平均年龄 72 岁与 80 岁），体重更大（95 岁与 80 岁）。 80 kg）和更高的血清肌酐（2.7 与 2.5 mg/dL）。平均估计肾小球滤过率在各组之间没有差异（24 与 24 mL·min <sup>-1</sup> ·1.73 m <sup>-2</sup> ）。治疗权重分析的逆概率，阿哌沙班 5 mg 与较高的出血风险相关（每 100 人年发生率 4.9 例与 2.9 例事件；发生率差异，每 100 人年 2.0 [95% CI，0.6-3.4] 例事件；次分布风险比，1.63 [95% CI, 1.04-2.54]）。阿哌沙班 5 mg 和 2.5 mg 组之间的卒中/全身性栓塞风险没有差异（每 100 人年分别有 3.3 例和 3.0 例事件；发生率差异为 0.2 [95 %] CI，-1.0 至 1.4] 每 100 人年事件；次分布风险比，1.01 [95% CI，0.59-1.73]），或死亡（每 100 人年 9.9 与 9.4 事件；发生率差异，0.5 [ 95每 100 人年发生事件 % CI，-1.6 至 2.6；风险比，1.03 [95% CI，0.77-1.38]）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：与 2.5 mg 相比，使用 5 mg 阿哌沙班与心房颤动和严重慢性肾脏病患者的出血风险较高相关，但中风/全身性栓塞或死亡风险没有差异，支持阿哌沙班的剂量建议欧洲药品管理局以肾功能为基础，与美国食品和药物管理局发布的不同。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37681341/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230913081451&v=2.17.9.post6+86293ac">37681341</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065614>10.1161/CIRCULATIONAHA.123.065614</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37681341</guid><pubDate> Fri, 08 Sep 2023 06:00:00 -0400</pubDate><dc:creator>徐云文</dc:creator><dc:creator>亚历克斯·R·张</dc:creator><dc:creator>莱斯利·英克</dc:creator><dc:creator>玛拉·麦克亚当斯-德马科</dc:creator><dc:creator>摩根·E·格拉姆斯</dc:creator><dc:creator>申正林</dc:creator><dc:date>2023-09-08</dc:date><dc:source>循环</dc:source><dc:title>阿哌沙班剂量与心房颤动和严重慢性肾脏病患者安全性和有效性结果的关系</dc:title><dc:identifier>下午:37681341</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.065614</dc:identifier></item><item><title>与参与高级护理改善捆绑付款相关的心血管支出、护理利用和临床结果的变化</title><link/>https://pubmed.ncbi.nlm.nih.gov/37681315/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230913081451&amp;v=2.17.9.post6+86293ac<description>结论：参与 BPCI-A 与模型中提供的心血管医疗事件或手术的支出减少、护理使用的改变或质量提高无关。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 9 月 8 日。doi：10.1161/CIRCULATIONAHA.123.065109。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：高级护理改善捆绑付款 (BPCI-A) 是一项 Medicare 计划，旨在激励减少从住院开始到出院后 90 天结束的护理支出。心血管疾病是 Medicare 支出的重要驱动因素，是 BPCI-A 关注的领域之一。目前尚不清楚 BPCI-A 是否与模型中 3 种心血管医疗事件或 5 种心血管手术的支出减少或质量提高相关。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：在这项回顾性队列研究中，我们使用 Medicare 索赔对 2017 年 1 月 1 日至 2019 年 9 月 30 日期间出院的患者进行了双重差分分析，以评估 BPCI-A 医院与匹配的非参与对照医院之间的差异。结果是与对照组相比，实施 BPCI-A 之前和之后 BPCI-A 医院心脏医疗和手术条件的支出差异变化。次要结果包括患者复杂性、护理使用、在家健康天数、再入院、和死亡率。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：BPCI-A 医院心脏医疗事件的基线支出为 25 606 美元。BPCI-A 与对照医院心脏医疗事件支出的差异变化为 16 美元（95% CI，-228 美元至 261 美元； <i>P</i> = 0.90）。 BPCI-A 医院心脏手术发作的基线支出为 37 961 美元。心脏手术发作支出的差异变化为 171 美元（95% CI，-429 美元至 772 美元； <i>P</i> = 0.58）。医生护理方面的差异变化很小在 BPCI-A 与对照医院相比，90 天再入院率没有显着差异（差异变化，0.27% [95% CI，-0.25% 至对于医疗事件，差异变化为 0.80%]；对于手术事件，差异变化为 0.31% [95% CI，-0.98% 至 1.60%]）或死亡率（差异变化，对于手术事件，为 -0.14% [95% CI，-0.50% 至 0.23%]医疗事件；差异变化，-0.36% [95% CI，-1.25% 至 0.54%]（对于手术事件）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: Participation in BPCI-A was not associated with spending reductions, changes in care use, or quality improvements for the cardiovascular medical events or procedures offered in the model.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37681315/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230913081451&v=2.17.9.post6+86293ac">37681315</a> | DOI: <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065109>10.1161/CIRCULATIONAHA.123.065109</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37681315</guid><pubDate> Fri, 08 Sep 2023 06:00:00 -0400</pubDate><dc:creator> Sukruth A Shashikumar</dc:creator><dc:creator> Jie Zheng</dc:creator><dc:creator> E John Orav</dc:creator><dc:creator> Arnold M Epstein</dc:creator><dc:creator> Karen E Joynt Maddox</dc:creator><dc:date> 2023-09-08</dc:date><dc:source> Circulation</dc:source><dc:title> Changes in Cardiovascular Spending, Care Utilization, and Clinical Outcomes Associated With Participation in Bundled Payments for Care Improvement Advanced</dc:title><dc:identifier> pmid:37681315</dc:identifier><dc:identifier> doi:10.1161/CIRCULATIONAHA.123.065109</dc:identifier></item><item><title> Extracellular Perinexal Separation Is a Principal Determinant of Cardiac Conduction</title><link/> https://pubmed.ncbi.nlm.nih.gov/37681314/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230913081451&amp;v=2.17.9.post6+86293ac<description> CONCLUSIONS: Cardiac conduction does not correlate with extracellular resistance but is biphasically related to perinexal separation, providing evidence that the relationship between CV and extracellular volume is determined by ephaptic mechanisms under conditions of normal gap junctional coupling. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Circ Res. 2023 Sep 8. doi: 10.1161/CIRCRESAHA.123.322567. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND: Cardiac conduction is understood to occur through gap junctions. Recent evidence supports ephaptic coupling as another mechanism of electrical communication in the heart. Conduction via gap junctions predicts a direct relationship between conduction velocity (CV) and bulk extracellular resistance. By contrast, ephaptic theory is premised on the existence of a biphasic relationship between CV and the volume of specialized extracellular clefts within intercalated discs such as the perinexus. Our objective was to determine the relationship between ventricular CV and structural changes to micro- and nanoscale extracellular spaces. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: Conduction and Cx43 (connexin43) protein expression were quantified from optically mapped guinea pig whole-heart preparations perfused with the osmotic agents albumin, mannitol, dextran 70 kDa, or dextran 2 MDa. Peak sodium current was quantified in isolated guinea pig ventricular myocytes. Extracellular resistance was quantified by impedance spectroscopy. Intercellular communication was assessed in a heterologous expression system with fluorescence recovery after photobleaching. Perinexal width was quantified from transmission electron micrographs. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: CV primarily in the transverse direction of propagation was significantly reduced by mannitol and increased by albumin and both dextrans. The combination of albumin and dextran 70 kDa decreased CV relative to albumin alone. Extracellular resistance was reduced by mannitol, unchanged by albumin, and increased by both dextrans. Cx43 expression and conductance and peak sodium currents were not significantly altered by the osmotic agents. In response to osmotic agents, perinexal width, in order of narrowest to widest, was albumin with dextran, 70 kDa; albumin or dextran, 2 MDa; dextran, 70 kDa or no osmotic agent, and mannitol. When compared in the same order, CV was biphasically related to perinexal width. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: Cardiac conduction does not correlate with extracellular resistance but is biphasically related to perinexal separation, providing evidence that the relationship between CV and extracellular volume is determined by ephaptic mechanisms under conditions of normal gap junctional coupling.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37681314/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230913081451&v=2.17.9.post6+86293ac">37681314</a> | DOI: <a href=https://doi.org/10.1161/CIRCRESAHA.123.322567>10.1161/CIRCRESAHA.123.322567</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37681314</guid><pubDate> Fri, 08 Sep 2023 06:00:00 -0400</pubDate><dc:creator> William P Adams</dc:creator><dc:creator> Tristan B Raisch</dc:creator><dc:creator> Yajun Zhao</dc:creator><dc:creator> Rafael Davalos</dc:creator><dc:creator> Sarah Barrett</dc:creator><dc:creator> D Ryan King</dc:creator><dc:creator> Chandra B Bain</dc:creator><dc:creator> Katrina Colucci-Chang</dc:creator><dc:creator> Grace A Blair</dc:creator><dc:creator> Alexandra Hanlon</dc:creator><dc:creator> Alicia Lozano</dc:creator><dc:creator> Rengasayee Veeraraghavan</dc:creator><dc:creator> Xiaoping Wan</dc:creator><dc:creator> Isabelle Deschene</dc:creator><dc:creator> James W Smyth</dc:creator><dc:creator> Gregory S Hoeker</dc:creator><dc:creator> Robert G Gourdie</dc:creator><dc:creator> Steven Poelzing</dc:creator><dc:date> 2023-09-08</dc:date><dc:source> Circulation research</dc:source><dc:title> Extracellular Perinexal Separation Is a Principal Determinant of Cardiac Conduction</dc:title><dc:identifier> pmid:37681314</dc:identifier><dc:identifier> doi:10.1161/CIRCRESAHA.123.322567</dc:identifier></item><item><title> Clonal Hematopoiesis in Clinical and Experimental Heart Failure With Preserved Ejection Fraction</title><link/> https://pubmed.ncbi.nlm.nih.gov/37681311/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230913081451&amp;v=2.17.9.post6+86293ac<description> CONCLUSIONS: CH is associated with worse heart function and prognosis in patients with HFpEF, and a murine experimental model of Tet2-mediated CH displays greater features of HFpEF. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Circulation</b> . 2023 Sep 8. doi: 10.1161/CIRCULATIONAHA.123.064170. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND: Clonal hematopoiesis (CH), which results from an array of nonmalignant driver gene mutations, can lead to altered immune cell function and chronic disease, and has been associated with worse outcomes in patients with heart failure (HF) with reduced ejection fraction. However, the role of CH in the prognosis of HF with preserved ejection fraction (HFpEF) has been understudied. This study aimed to characterize CH in patients with HFpEF and elucidate its causal role in a murine model. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: Using a panel of 20 candidate CH driver genes and a variant allele frequency cutoff of 0.5%, ultradeep error-corrected sequencing identified CH in a cohort of 81 patients with HFpEF (mean age, 71±6 years; ejection fraction, 63±5%) and 36 controls without a diagnosis of HFpEF (mean age, 74±7 years; ejection fraction, 61.5±8%). </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: Compared with controls, there was an enrichment of <i>TET2</i> -mediated CH in the HFpEF patient cohort (12% versus 0%, respectively; <i>P</i> =0.02). In the HFpEF cohort, patients with CH exhibited exacerbated diastolic dysfunction in terms of E/e&#39; (14.9 versus 11.7, respectively; <i>P</i> =0.0096) and E/A (1.69 versus 0.89, respectively; <i>P</i> =0.0206) compared with those without CH. The association of CH with exacerbated diastolic dysfunction was corroborated in a validation cohort of 59 individuals with HFpEF. In accordance, patients with HFpEF with CH and age ≥70 years exhibited worse prognosis in terms of 5-year cardiovascular-related hospitalization rate (hazard ratio, 5.06; <i>P</i> =0.042) compared with patients with HFpEF without CH and age ≥70 years. To investigate the causal role of CH in HFpEF, nonconditioned mice underwent adoptive transfer with <i>Tet2</i> -wild-type or <i>Tet2</i> -deficient bone marrow and were subsequently subjected to a high-fat diet/L-NAME (N <sub>ω</sub> -nitro-l-arginine methyl ester) combination treatment to induce features of HFpEF. This model of <i>Tet2</i> -CH exacerbated cardiac hypertrophy by heart weight/tibia length and cardiomyocyte size, diastolic dysfunction by E/e&#39; and left ventricular end-diastolic pressure, and cardiac fibrosis compared with the <i>Tet2</i> -wild-type condition. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: CH is associated with worse heart function and prognosis in patients with HFpEF, and a murine experimental model of <i>Tet2</i> -mediated CH displays greater features of HFpEF.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37681311/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230913081451&v=2.17.9.post6+86293ac">37681311</a> | DOI: <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.064170>10.1161/CIRCULATIONAHA.123.064170</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37681311</guid><pubDate> Fri, 08 Sep 2023 06:00:00 -0400</pubDate><dc:creator> Jesse Cochran</dc:creator><dc:creator> Yoshimitsu Yura</dc:creator><dc:creator> Mark C Thel</dc:creator><dc:creator> Heather Doviak</dc:creator><dc:creator> Ariel H Polizio</dc:creator><dc:creator> Yuka Arai</dc:creator><dc:creator> Yohei Arai</dc:creator><dc:creator> Keita Horitani</dc:creator><dc:creator> Eunbee Park</dc:creator><dc:creator> Nicholas W Chavkin</dc:creator><dc:creator> Anupreet Kour</dc:creator><dc:creator> Soichi Sano</dc:creator><dc:creator> Nitin Mahajan</dc:creator><dc:creator> Megan Evans</dc:creator><dc:creator> Mahalia Huba</dc:creator><dc:creator> Nadia Martinez Naya</dc:creator><dc:creator> Hanna Sun</dc:creator><dc:creator> Youngho Ban</dc:creator><dc:creator> Karen K Hirschi</dc:creator><dc:creator> Stefano Toldo</dc:creator><dc:creator> Antonio Abbate</dc:creator><dc:creator> Todd E Druley</dc:creator><dc:creator> Frederick L Ruberg</dc:creator><dc:creator> Mathew S Maurer</dc:creator><dc:creator> Justin A Ezekowitz</dc:creator><dc:creator> Jason RB Dyck</dc:creator><dc:creator> Kenneth Walsh</dc:creator><dc:date> 2023-09-08</dc:date><dc:source> Circulation</dc:source><dc:title> Clonal Hematopoiesis in Clinical and Experimental Heart Failure With Preserved Ejection Fraction</dc:title><dc:identifier> pmid:37681311</dc:identifier><dc:identifier> doi:10.1161/CIRCULATIONAHA.123.064170</dc:identifier></item><item><title> Cardiac Aging Is Promoted by Pseudohypoxia Increasing p300-Induced Glycolysis</title><link/> https://pubmed.ncbi.nlm.nih.gov/37681309/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230913081451&amp;v=2.17.9.post6+86293ac<description> CONCLUSIONS: Taken together, our results suggest how epigenetic dysregulation of glycolysis pathway enhancers could potentially be targeted to treat heart failure in the elderly. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Circ Res. 2023 Sep 8. doi: 10.1161/CIRCRESAHA.123.322676. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RATIONALE: Heart failure is typical in the elderly. Metabolic remodeling of cardiomyocytes underlies inexorable deterioration of cardiac function with aging: glycolysis increases at the expense of oxidative phosphorylation, causing an energy deficit contributing to impaired contractility. Better understanding of the mechanisms of this metabolic switching could be critical for reversing the condition. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> OBJECTIVE: To investigate the role of 3 histone modifications (H3K27ac, H3K27me3, and H3K4me1) in the metabolic remodeling occurring in the aging heart. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: We report a set of species-conserved enhancers associated with transcriptional changes underlying age-related metabolic remodeling in cardiomyocytes. Activation of the enhancer region of <i>Hk2</i> -a key glycolysis pathway gene-was fostered in old age-onset mouse heart by pseudohypoxia, wherein hypoxia-related genes are expressed under normal O <sub>2</sub> levels, via increased activity of the transcriptional coactivator p300 (E1A-associated binding protein p300)/CBP (CREB-binding protein). Pharmacological inhibition of p300/CBP before the onset of cardiac aging led to a more aerobic, less glycolytic, metabolic state, improved heart contractility, and overall blunting of cardiac decline. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: Taken together, our results suggest how epigenetic dysregulation of glycolysis pathway enhancers could potentially be targeted to treat heart failure in the elderly.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37681309/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230913081451&v=2.17.9.post6+86293ac">37681309</a> | DOI: <a href=https://doi.org/10.1161/CIRCRESAHA.123.322676>10.1161/CIRCRESAHA.123.322676</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37681309</guid><pubDate> Fri, 08 Sep 2023 06:00:00 -0400</pubDate><dc:creator> Simone Serio</dc:creator><dc:creator> Christina Pagiatakis</dc:creator><dc:creator> Elettra Musolino</dc:creator><dc:creator> Arianna Felicetta</dc:creator><dc:creator> Pierluigi Carullo</dc:creator><dc:creator> Javier Laura Frances</dc:creator><dc:creator> Laura Papa</dc:creator><dc:creator> Giacomo Rozzi</dc:creator><dc:creator> Nicolò Salvarani</dc:creator><dc:creator> Michele Miragoli</dc:creator><dc:creator> Rosalba Gornati</dc:creator><dc:creator> Giovanni Bernardini</dc:creator><dc:creator> Gianluigi Condorelli</dc:creator><dc:creator> Roberto Papait</dc:creator><dc:date> 2023-09-08</dc:date><dc:source> Circulation research</dc:source><dc:title> Cardiac Aging Is Promoted by Pseudohypoxia Increasing p300-Induced Glycolysis</dc:title><dc:identifier> pmid:37681309</dc:identifier><dc:identifier> doi:10.1161/CIRCRESAHA.123.322676</dc:identifier></item><item><title> An apple in the heart: a rare case of cardiac hyper-immunoglobulin E syndrome</title><link/> https://pubmed.ncbi.nlm.nih.gov/37680109/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230913081451&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Sep 8:ehad565. doi: 10.1093/eurheartj/ehad565. Online ahead of print.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37680109/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230913081451&v=2.17.9.post6+86293ac">37680109</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad565>10.1093/eurheartj/ehad565</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37680109</guid><pubDate> Fri, 08 Sep 2023 06:00:00 -0400</pubDate><dc:creator> Jie Yin</dc:creator><dc:creator> Xiao-Hang Liu</dc:creator><dc:creator> Wei Chen</dc:creator><dc:date> 2023-09-08</dc:date><dc:source> European heart journal</dc:source><dc:title> An apple in the heart: a rare case of cardiac hyper-immunoglobulin E syndrome</dc:title><dc:identifier> pmid:37680109</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad565</dc:identifier></item><item><title> Silencing liver angiotensinogen synthesis as a novel approach to hypertension management: promises and challenges</title><link/> https://pubmed.ncbi.nlm.nih.gov/37680108/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230913081451&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Sep 8:ehad593. doi: 10.1093/eurheartj/ehad593. Online ahead of print.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37680108/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230913081451&v=2.17.9.post6+86293ac">37680108</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad593>10.1093/eurheartj/ehad593</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37680108</guid><pubDate> Fri, 08 Sep 2023 06:00:00 -0400</pubDate><dc:creator> Giovanna Liuzzo</dc:creator><dc:creator> Massimo Volpe</dc:creator><dc:date> 2023-09-08</dc:date><dc:source> European heart journal</dc:source><dc:title> Silencing liver angiotensinogen synthesis as a novel approach to hypertension management: promises and challenges</dc:title><dc:identifier> pmid:37680108</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad593</dc:identifier></item></channel></rss>